Ultra-Long-Acting Oral Antipsychotic for Treatment of Schizophrenia
Conference – American Society of Clinical Psychopharmacology (ASCP) 2021 (June 1-4, 2021) Date – June 03, 2021 Mode – Virtual A new phase II study suggested improved quality of life and treatment adherence in schizophrenic patients with a novel, ultra-long-acting formulation of risperidone (LYN-005). The study comprised of 32 schizophrenia patients received immediate-release (IR) risperidone […]